A Possible Novel Anti-Inflammatory Mechanism for the Pharmacological Prolyl Hydroxylase Inhibitor 3,4-Dihydroxybenzoate: Implications for Use as a Therapeutic for Parkinson’s Disease

Shankar J. Chinta(Buck Institute for Research on Aging), Julie K. Andersen(Buck Institute for Research on Aging)
Parkinson s Disease
January 1, 2012
Cited by 17


Related Papers